WHO WE ARE
We are pioneering high throughput in vivo testing to develop novel cell therapies for solid tumors, autoimmune diseases, and beyond.
Our platform uses ultra-high resolution spatial multi-omics and is powered by proprietary approaches using computer vision, cell therapy design, and pooled screening.
These novel capabilities solve critical issues around understanding how cell therapies navigate the three-dimensional tissue architecture including tumor microenvironments and allow the measurement of cell-to-cell and cell-to-environment interactions.
With an iterative cycle that continuously learns and improves, we aim to rationally design and develop more effective and safe solid tumor cell therapies providing medical teams and their patients novel treatment options to combat cancer and autoimmune diseases.
THE PROBLEMS WE SOLVE
Current cell therapy design processes require making a choice between inexpensive but inaccurate high throughput in vitro screening systems or more accurate expensive low throughput in vivo screening systems
The 90% of cancer patients with solid tumors have no cell therapy options
HOW WE SOLVE THEM
We have developed a proprietary end-to-end platform for cell engineering designed to enable three-dimensional solutions that understand tumor and tissue structure, function and therapy response
WHY IT’S IMPORTANT
Our platform designs cell therapies faster with more rigorous analysis and testing compressing years of work into a single experiment
Our platform tests 1000s of potential therapies in a single mouse, opening the door to discovering new superior cell therapy designs, and enabling new ways to optimize therapy selection for development